Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb

Platelets

Volumn 26, Issue 1, 2015, Pages 43-47

  Komosa, A ^a   Siller Matula, J M ^b   Kowal, J ^c   Lesiak, M ^a   Siniawski, A ^a   Maczynski M ^a   Michalak, M ^a   Mularek Kubzdela, T ^a   Grajek, S ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Department of Clinical Pharmacology ^*  (Austria)

Author keywords

Aggregation; Antiplatelet therapy; Clopidogrel; Generic; Platelets

Indexed keywords

CLOPIDOGREL; GENERIC DRUG; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG FORMULATION; FEMALE; HOSPITAL ADMISSION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; DRUG EFFECTS; MEDICINAL CHEMISTRY; MIDDLE AGED; RISK FACTOR; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADULT; CHEMISTRY, PHARMACEUTICAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84921478940     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.877581     Document Type: Article

References (29)

1. Lionberger R, Jiang W, Huang SM, Geba G. Confidence in generic drug substitution. Clin Pharmacol Ther 2013;94:938-940.
2. WHO Technical Report Series No. 937: Annex 7 (pdf) WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO Technical Report Series No. 937): Annex 7 - Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability, May 2006. htpp://www.whqlibdoc.who.int/trs/who-trs-937-eng.pdf [last accessed 15 June 2008].
3. Jeong Y-H, Koh J-S, Kang M-K, Ahn Y-J, Kim-S I, Park Y, Hwang SJ, Kwak CH, Hwang JY. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: Results of the ACCEL-GENERIC Study. Korean J Intern Med 2010;25:154-161.
4. Sambu N, Radhakrishnan A, Curzen N. A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel. J Cardiovasc Pharmacol 2012;60:495-501.
5. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart A, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA 2008;300:2514-2526.
6. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost 2012;10:529-542.
7. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013; 167:2018-2023.
8. Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012;23:510-525.
9. Neubauer H, Krüger JC, Lasak S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: A crossover study. Clin Res Cardiol 2009;98:533-540.
10. Kaur P, Chaurasia CS, Davit BM, Conner DP. Bioequivalence study designs for generic solid oral anticancer drug products: Scientific and regulatory considerations. J Clin Pharmacol 2013;53: 1252-1260.
11. Oberhaensli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer J-C, Baeriswyl G, Goy JJ, Cook S. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial. Arch Cardiovasc Dis 2012;105:587-592.
12. Kim SD, Kang W, Lee H, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in health Korean Male subjects. Clin Ther 2009;31:793-803.
13. Borsiczky B, Sarszegi Z, Konyi A, Szabados S, Gaszner B. The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study. Thromb Res 2012;129:700-703.
14. Siller-Matula JM, Trenk D, Schroer K, Gawaz M, Kristensen SD, Storey RF, Huber K. Response variability to P2Y12 receptor inhibitors: Expectations and reality. JACC Cardiovasc Interv 2013;6: 1111-1128.
15. Bonello L, Tantry US, Marucci R, Blindt R, Angiolillo D, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2012;56: 919-1033.
16. Fuentes E, Fuentes F, Andrés V, Pello OM, Font de Mora J, Palomo I. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2013;24:255-262.
17. Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C, Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013;167:430-435.
18. Manigacapra F, Peace A, Barbato E, Patti G, Gatto L, Ricottini E, De Bruyne B, Di Sciascio G, Wijns W. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets 2013. [Epub ahead of print].
19. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors - Where do we stand in 2012? World J Gastroenterol 2012;18:2161-2171.
20. Yin T, Miyata T. Pharmacogenomics of clopidogrel: Evidence and perspectives. Thromb Res 2011;128:307-316.
21. Abdel-Latif A, Smyth S. Preventing platelet thrombosis with a PAR1 pepducin. Circulation 2012;126:13-15.
22. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27: 1166-1173.
23. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 2012;60:193-199.
24. Jeong Y-H, Kim-S I, Park Y, Kang MK, Koh JS, Hwang SJ, Kwak CH, Hwang JY. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: Results of the ACCEL DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010;3: 731-741.
25. Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Montalescot G. Can we overridden clopidogrel resistance? Circulation 2009;119:2854-2857.
26. Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Quayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response - The TAILOR (Thrombocytes and Individualization of Oral antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 2013. [Epub ahead of print].
27. Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets 2013;24:615-624.
28. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
29. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that preexistent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2007;5:75-81.